Information  X 
Enter a valid email address

PureTech Health PLC (PRTC)

  Print      Mail a friend

Wednesday 29 August, 2018

PureTech Health PLC

Notice of Results

RNS Number : 0604Z
PureTech Health PLC
29 August 2018
 

 

29 August 2018

 

PureTech Health plc

 

Notice of Half-Yearly Results

 

PureTech Health plc (LSE: PRTC), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis, expects to announce its half-yearly results for the six months ended 30 June 2018 at 7.00am BST on Tuesday 11 September 2018.

 

About PureTech Health

PureTech Health (LSE: PRTC) is an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis. The Company has developed deep insight into the connection between the individual components of these systems and the resulting role in many chronic diseases, which represent the majority of healthcare spend and have proven resistant to established therapeutic approaches. By harnessing this emerging field of human biology, PureTech Health is developing new categories of medicines with the potential to have great impact on people with serious diseases.

 

PureTech Health is advancing a rich pipeline of innovative therapies across two divisions: the Affiliates division and the Internal division. Its Affiliates division includes two product candidates that are preparing for potential regulatory approval in the United States and Europe as well as other novel clinical and pre-clinical programmes. These affiliates are developing ground-breaking platforms and therapeutic candidates in collaboration with some of the world's leading experts.

 

PureTech's Internal division is advancing a pipeline fuelled by recent discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. These programmes leverage the transport and biodistribution of various immune system components for the targeted treatment of diseases with major unmet needs, including cancers, autoimmune diseases, and neuroimmune disorders.

 

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

 

Contact:

 

Investors

EU Media

Allison Mead Talbot

+1 617 651 3156

[email protected]

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

[email protected]

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORBCGDIDSDBGII

a d v e r t i s e m e n t